Glucose conjugation for the specific targeting and treatment of cancer
Open accessThe DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Cancers of diverse origins exhibit marked glucose avidity and high rates of aerobic glycolysis. Increased understanding of this dysfunctional metabolism known as the Warburg effect has led to an interest in targeting it for cancer therapy. One promising strategy for such targeting is glycoconjugation, the linking of a drug to glucose or another sugar. This review summarizes the most salient examples of glycoconjugates, in which known cytotoxins or targeted anticancer therapeutics have been linked to glucose (or another glucose transporter substrate sugar) for improved cancer targeting and selectivity. Building on these examples, this review also provides a series of guidelines for the design and mechanistic evaluation of future glycoconjugates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Today this phenomenon is known as the Warburg effect and is recognized as one of the hallmarks of cancer [3].”
BackgroundWarburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“Almost a century ago, the German scientist Otto Warburg observed that cancerous tissues consume large amounts of glucose compared to non-transformed tissue and have high rates of aerobic glycolysis [1, 2].”
BackgroundThe metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416 · cited 1×
“Almost a century ago, the German scientist Otto Warburg observed that cancerous tissues consume large amounts of glucose compared to non-transformed tissue and have high rates of aerobic glycolysis [1, 2].”
BackgroundTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 1×
“Another antibody-drug conjugate, Kadcyla (trastuzumab emtansine; Figure 2b), received US FDA approval in February 2013 for the treatment of HER2-positive breast cancer following the EMILIA clinical trial [15].”
BackgroundTargeting cancer metabolism: a therapeutic window opens
Vander Heiden, M. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,411 · cited 1×
“Most efforts have focused on using small molecules to inhibit the function of metabolic enzymes, as comprehensively reviewed elsewhere [10, 11].”
BackgroundParker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., & Leamon, C. P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.026 · Cited by 1,197 · cited 1×
“For this reason, folate receptor α (FR-α) is overexpressed in an estimated 40% of human cancers (it is expressed only by certain types of epithelial cells in healthy individuals) [17, 18].”
BackgroundDe Vivo, D. C., Trifiletti, R. R., Jacobson, R. I., Ronen, G. M., Behmand, R. A., & Harik, S. I. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109053251006 · Cited by 800 · cited 1×
“Incidentally, humans born with a mutated, functionallyimpaired GLUT-1 transporter experience a severe phenotype known as De Vivo disease which results in mental retardation, seizures, and a host of neurological deficits, underscoring the importance of GLUT-1 in supplying glucose to the nervous system [95].”
BackgroundSenter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763 · cited 1×
“Adcertis is thought to enter cancer cells via CD30 receptor-mediated endocytosis and subsequently be trafficked to endosomes, where a combination of degradative enzymes and increased acidity lead to cleavage to the active tubulin inhibitor [14].”
BackgroundGenes of glycolysis are ubiquitously overexpressed in 24 cancer classes
Altenberg, B., & Greulich, K. O. (2004) · Genomics · doi:10.1016/j.ygeno.2004.08.010 · Cited by 659 · cited 1×
“Glycolytic enzymes, as well as the insulinindependent glucose transporter GLUT-1, are widely overexpressed in human cancers [4, 5], and high expression levels of these proteins in tumor biopsy samples correlate with poor cancer prognosis, making them attractive therapeutic targets [6–9].”
BackgroundFolate-targeted therapeutic and imaging agents for cancer
Low, P. S., & Kularatne, S. A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.022 · Cited by 585 · cited 1×
“For this reason, folate receptor α (FR-α) is overexpressed in an estimated 40% of human cancers (it is expressed only by certain types of epithelial cells in healthy individuals) [17, 18].”
BackgroundLiu, Y., Cao, Y., Zhang, W., Bergmeier, S., Qian, Y., Akbar, H., Colvin, R., Ding, J., Tong, L., Wu, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0131 · Cited by 555 · cited 1×
“More recently, GLUT inhibitors have been discovered through screening and design studies, such as the GLUT-1 inhibitor fasentin [91] and the GLUT-1 inhibitor WZB117 [92].”
BackgroundGlucose transporters: expression, regulation and cancer
MEDINA, R. A., & OWEN, G. I. (2002) · Biological Research · doi:10.4067/s0716-97602002000100004 · Cited by 472 · cited 4×
“There are at least 12 classes of GLUT transporters (both insulin-dependent and –independent) which transport glucose or hexoses alone, as well as several in which the transport of glucose is coupled with sodium, as detailed by Medina [5].”
BackgroundInfluentialKunkel, M., Reichert, T. E., Benz, P., Lehr, H., Jeong, J., Wieand, S., Bartenstein, P., Wagner, W., & Whiteside, T. L. (2003) · Cancer · doi:10.1002/cncr.11159 · Cited by 390
GLUT1 Expression Is Increased in Hepatocellular Carcinoma and Promotes Tumorigenesis
Amann, T., Maegdefrau, U., Hartmann, A., Agaimy, A., Marienhagen, J., Weiss, T. S., Stoeltzing, O., Warnecke, C., Schölmerich, J., Oefner, P. J., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080596 · Cited by 368
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
Ben-Haim, S., & Ell, P. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.054205 · Cited by 351 · cited 1×
“18F-FDG has been used to visualize tumors and their metastases due to the tendency of these cancerous tissues to take up glucose at a higher rate than most normal tissues (as shown in Figure 1b & 1c) [12, 13].”
BackgroundLeFevre, P. G. (1961) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)07001-2 · Cited by 309 · cited 2×
“Historically, competition with radiolabeled glucose [79] and changes in erythrocyte volume [85, 88] have been used in this model system.”
BackgroundMethodNew aspects of the Warburg effect in cancer cell biology
Bensinger, S. J., & Christofk, H. R. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.02.003 · Cited by 307 · cited 1×
“A second metric to determine which types of cancers would be good candidates for glycoconjugate targeting is to examine which cancers are clinically staged using 18F-FDG PET imaging, summarized in a recent review by Bensinger and Christofk [30].”
BackgroundExpression of GLUT1 and GLUT3 Glucose Transporters in Endometrial and Breast Cancers
Krzeslak, A., Wojcik-Krowiranda, K., Forma, E., Jozwiak, P., Romanowicz, H., Bienkiewicz, A., & Brys, M. (2012) · Pathology & Oncology Research · doi:10.1007/s12253-012-9500-5 · Cited by 279
Visentin, M., Zhao, R., & Goldman, I. D. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.002 · Cited by 253 · cited 1×
“Cancer cells prefer de novo nucleotide synthesis over the salvage pathway that is often favored by normal tissues [16].”
BackgroundYoshioka, K., Takahashi, H., Homma, T., Saito, M., Oh, K.-B., Nemoto, Y., & Matsuoka, H. (1996) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(95)00153-0 · Cited by 240 · cited 2×
“As previously discussed, 2-18F-fluoro-2-deoxyglucose (18F-FDG) is a widely established clinical tool that is a substrate for GLUT-1 and GLUT-3 transporters [82], and 2NBDG, in which the C2 hydroxyl is replaced by nitrogen and a bulky aromatic system, is a widely used fluorescent glucose bioprobe which has been shown t…”
BackgroundStructural requirements for binding to the sugar-transport system of the human erythrocyte
Barnett, J. E. G., Holman, G. D., & Munday, K. A. (1973) · Biochemical Journal · doi:10.1042/bj1310211 · Cited by 236 · cited 7×
“Historically, competition with radiolabeled glucose [79] and changes in erythrocyte volume [85, 88] have been used in this model system.”
BackgroundMethodInfluentialOverexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma.
Reske, S. N., Grillenberger, K. G., Glatting, G., Port, M., Hildebrandt, M., Gansauge, F., & Beger, H. G. (1997) · PubMed · Cited by 197
Young, C. D., Lewis, A. S., Rudolph, M. C., Ruehle, M. D., Jackman, M. R., Yun, U. J., Ilkun, O., Pereira, R., Abel, E. D., & Anderson, S. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023205 · Cited by 195 · cited 3×
“In examining the entry of 3H-2-deoxyglucose into cells, it was reported that shRNA-mediated GLUT-1 knockdown in a murine cell line which expressed GLUT-1 as its predominant GLUT transporter led to only a 25% reduction in 3H-2-deoxyglucose entry compared to control shRNA cells [94], presumably due to an increase in exp…”
BackgroundMethodInfluentialA novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death
Wood, T. E., Dalili, S., Simpson, C. D., Hurren, R., Mao, X., Saiz, F. S., Gronda, M., Eberhard, Y., Minden, M. D., Bilan, P. J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0569 · Cited by 195 · cited 1×
“More recently, GLUT inhibitors have been discovered through screening and design studies, such as the GLUT-1 inhibitor fasentin [91] and the GLUT-1 inhibitor WZB117 [92].”
BackgroundYamada, K., Nakata, M., Horimoto, N., Saito, M., Matsuoka, H., & Inagaki, N. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908048199 · Cited by 191 · cited 2×
“As previously discussed, 2-18F-fluoro-2-deoxyglucose (18F-FDG) is a widely established clinical tool that is a substrate for GLUT-1 and GLUT-3 transporters [82], and 2NBDG, in which the C2 hydroxyl is replaced by nitrogen and a bulky aromatic system, is a widely used fluorescent glucose bioprobe which has been shown t…”
BackgroundLeFevre, P. G., & Marshall, J. K. (1959) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)69717-0 · Cited by 172 · cited 12×
“However, glufosfamide's anticancer potency was markedly reduced upon co-treatment with 0.1 mM of the GLUT-1 transporter inhibitors phloretin and phlorizin, suggesting that the entry of glufosfamide into cells was at least partially GLUT receptor-mediated.”
BackgroundInfluentialAnticancer Agents That Counteract Tumor Glycolysis
Granchi, C., & Minutolo, F. (2012) · ChemMedChem · doi:10.1002/cmdc.201200176 · Cited by 166 · cited 1×
“Most efforts have focused on using small molecules to inhibit the function of metabolic enzymes, as comprehensively reviewed elsewhere [10, 11].”
BackgroundSinger, K., Kastenberger, M., Gottfried, E., Hammerschmied, C. G., Büttner, M., Aigner, M., Seliger, B., Walter, B., Schlösser, H., Hartmann, A., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25543 · Cited by 160
Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Gatter, K. C., Trarbach, T., Folprecht, G., Shi, M. M., Lebwohl, D., Jalava, T., Laurent, D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2918 · Cited by 133
Medicinal Chemistry of Paclitaxel and its Analogues
Fu, Y., Li, S., Zu, Y., Yang, G., Yang, Z., Luo, M., Jiang, S., Wink, M., & Efferth, T. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709789352277 · Cited by 132 · cited 2×
“Position 2′ of paclitaxel is crucial for the drug’s interaction with microtubules [55], so this compound is presumed to be a prodrug that required activation in cells (in vitro assays to assess whether glycoconjugates were able to modulate tubulin polymerization were not reported).”
BackgroundPohl, J., Bertram, B., Hilgard, P., Nowrousian, M. R., Stüben, J., & Wießler, M. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050248 · Cited by 130 · cited 4×
“plausible that the renal adverse effects may be at least partly due to toxic metabolites of ifosfamide generated during renal metabolism [34], but the anemia observed may stem from the fact that erythrocytes express high levels of GLUT-1 [49, 50].”
BackgroundInfluentialKunkel, M., Moergel, M., Stockinger, M., Jeong, J., Fritz, G., Lehr, H., & Whiteside, T. L. (2007) · Oral Oncology · doi:10.1016/j.oraloncology.2006.10.009 · Cited by 124
Targeting the Delivery of Glycan-Based Paclitaxel Prodrugs to Cancer Cells via Glucose Transporters
Lin, Y.-S., Tungpradit, R., Sinchaikul, S., An, F.-M., Liu, D.-Z., Phutrakul, S., & Chen, S.-T. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8006257 · Cited by 120 · cited 7×
“The conjugate depicted in Figure 4b was the most potent of the all glycoconjugates tested [53, 54].”
BackgroundInfluentialCheng, H., Cao, X., Xian, M., Fang, L., Cai, T., Ji, J. J., Tunac, J. B., Sun, D., & Wang, P. G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049693a · Cited by 119 · cited 1×
“These include glucose, lactose, and galactose conjugates of the heat shock protein 90 inhibitor geldanamycin [70], glucose conjugates of the natural product cadalene [71], glycoconjugates of the DNA alkylator duocarmycin SA [72, 73], and glucose conjugates of the lipoxygenase inhibitor nordihydroguaiaretic acid [74].”
BackgroundPreclinical Antitumor Activity of a Novel Folate-Targeted Dual Drug Conjugate
Leamon, C. P., Reddy, J. A., Vlahov, I. R., Westrick, E., Dawson, A., Dorton, R., Vetzel, M., Santhapuram, H. K., & Wang, Y. (2007) · Molecular Pharmaceutics · doi:10.1021/mp070049c · Cited by 109 · cited 1×
“Both the disulfide and peptide bonds are expected to be cleaved in intracellular endosomal compartments [20].”
BackgroundFisher, J. F., Harrison, A. W., Bundy, G. L., Wilkinson, K. F., Rush, B. D., & Ruwart, M. J. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00114a026 · Cited by 101 · cited 1×
“In 1991, several glycopeptide analogs of the antihypertensive peptide renin, including a mannose and a 2-(acetylamino)-2-deoxyglucose linked to renin via a C1 amide, were shown to have increased serum half-life compared to their aglycones [31].”
BackgroundHalmos, T., Santarromana, M., Antonakis, K., & Scherman, D. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00796-0 · Cited by 101 · cited 13×
“This strategy is inspired by the widespread clinical use of 2-deoxy-2-( 18 F)uoro-D-glucose ( 18 F-FDG; Fig.”
BackgroundInfluentialHénin, Y., Gouyette, C., Schwartz, O., Debouzy, J. C., Neumann, J., & Tam, H. D. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00110a011 · Cited by 100 · cited 1×
“The synthesis of glucose and mannose phosphotriester conjugates of the anti-retroviral nucleotide analog 3′-azido-3′-deoxythymidine (AZT) was also reported in 1991[32]; these derivatives were shown to have comparable antiviral efficacy and enhanced targeting to the central nervous system (presumably via GLUT transport…”
BackgroundCiuleanu, T., Pavlovsky, A. V., Bodoky, G., Garin, A. M., Langmuir, V. K., Kroll, S., & Tidmarsh, G. F. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.12.022 · Cited by 98 · cited 1×
“In a best supportive care phase III trial in terminal pancreatic cancer patients who had experienced disease progression in spite of gemcitabine treatment, treatment with 4500 mg/m2 glufosfamide plus best supportive care (analgesics, antibiotics, and other agents with no anti-tumor effects) led to an 18% increase in s…”
BackgroundGlut-1 Expression Correlates with Basal-like Breast Cancer
Hussein, Y. R., Bandyopadhyay, S., Semaan, A. Y., Ahmed, Q. F., Albashiti, B., Jazaerly, T., Nahleh, Z. A., & Ali‐Fehmi, R. (2011) · Translational Oncology · doi:10.1593/tlo.11256 · Cited by 92
Kim, W. H., Lee, J., Jung, D., & Williams, D. R. (2012) · Sensors · doi:10.3390/s120405005 · Cited by 90 · cited 1×
“A fourth approach is the use of fluorescently-labeled glucose bioprobes, as reviewed recently [96].”
BackgroundStewart, G. D. (1994) · Oncology Reports · doi:10.3892/or_00000180 · Cited by 89
Targeted Cancer Therapy with a 2-Deoxyglucose-Based Adriamycin Complex
Cao, J., Cui, S., Li, S., Du, C., Tian, J., Wan, S., Qian, Z., Gu, Y., Chen, W. R., & Wang, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2072 · Cited by 84 · cited 7×
“This adriamycin glycoconjugate was designed to enhance the selectivity of adriamycin to cancer cells, and thus to counteract the dose-limiting toxicity of adriamycin treatment on healthy tissues (notably the heart, liver, and kidneys) [69].”
BackgroundInfluentialFenske, W., Völker, H.-U., Adam, P., Hahner, S., Johanssen, S., Wortmann, S., Schmidt, M., Morcos, M., Müller-Hermelink, H.-K., Allolio, B., et al. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0211 · Cited by 84
Unique cytochalasin B binding characteristics of the hepatic glucose carrier
Axelrod, J. D., & Pilch, P. F. (1983) · Biochemistry · doi:10.1021/bi00278a025 · Cited by 80 · cited 1×
“cytochalasin B (a pan-GLUT transporter inhibitor [89, 90]).”
Mueckler, M., & Makepeace, C. (2009) · Biochemistry · doi:10.1021/bi900521n · Cited by 80 · cited 1×
“Kinetic and computational modeling studies using glucose analogs suggest that the hydroxyl groups at positions 1 and 3, and the pyran oxygen 5 in glucose’s closed conformation, are involved in stabilizing hydrogen bonding interactions with amino acid residues within the transporter [79, 80].”
BackgroundExpression of HIF-1α and Glut-1 in human bladder cancer
Palit, V., Phillips, R., Puri, R., Shah, T., & Bibby, M. (2005) · Oncology Reports · doi:10.3892/or.14.4.909 · Cited by 76
Zhou, H., Luby‐Phelps, K., Mickey, B., Habib, A. A., Mason, R. P., & Zhao, D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008051 · Cited by 75
Park, J., Lee, H. Y., Cho, M., & Park, S. B. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200604364 · Cited by 75
Semaan, A. Y., Munkarah, A. R., Arabi, H., Bandyopadhyay, S., Seward, S. M., Kumar, S., Qazi, A. M., Hussein, Y., Morris, R. T., & Ali‐Fehmi, R. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.11.019 · Cited by 72
Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II
Gong, L., Zhuqingqing, C., Chen, P., Han, H., Peng, J., & Leng, X.-S. (2011) · Medical Oncology · doi:10.1007/s12032-011-9841-z · Cited by 70
Tietze, L. F., Major, F., & Schuberth, I. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600936 · Cited by 69 · cited 1×
“These include glucose, lactose, and galactose conjugates of the heat shock protein 90 inhibitor geldanamycin [70], glucose conjugates of the natural product cadalene [71], glycoconjugates of the DNA alkylator duocarmycin SA [72, 73], and glucose conjugates of the lipoxygenase inhibitor nordihydroguaiaretic acid [74].”
BackgroundMarom, E. M., Aloia, T. A., Moore, M.-B., Hara, M., Herndon, J. E., Harpole, D. H., Goodman, P. C., & Patz, E. F. (2001) · Lung Cancer · doi:10.1016/s0169-5002(00)00250-6 · Cited by 69 · cited 1×
“As previously discussed, 2-18F-fluoro-2-deoxyglucose (18F-FDG) is a widely established clinical tool that is a substrate for GLUT-1 and GLUT-3 transporters [82], and 2NBDG, in which the C2 hydroxyl is replaced by nitrogen and a bulky aromatic system, is a widely used fluorescent glucose bioprobe which has been shown t…”
BackgroundGluconjugates of 8-hydroxyquinolines as potential anti-cancer prodrugs
Oliveri, V., Giuffrida, M. L., Vecchio, G., Aiello, C., & Viale, M. (2012) · Dalton Transactions · doi:10.1039/c2dt12371a · Cited by 68 · cited 2×
“When the antiproliferative ability of the glucose conjugates and their parent aglycones was assessed, the glucose conjugates were found to be less potent than the aglycones [65], perhaps due to insufficient cleavage of prodrugs to their aglycones in cells.”
BackgroundCytochalasin B may shorten actin filaments by a mechanism independent of barbed end capping
Theodoropoulos, P. A., Gravanis, A., Tsapara, A., Margioris, A. N., Papadogiorgaki, E., Galanopoulos, V. K., & Stournaras, C. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90318-2 · Cited by 66 · cited 1×
“Cytochalasin B is known to be relatively toxic with several reported targets, including actin [93].”
BackgroundAssessment of Chemoselective Neoglycosylation Methods Using Chlorambucil as a Model
Goff, R. D., & Thorson, J. S. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101024j · Cited by 66 · cited 3×
“Like in Thorson’s earlier exploration of neoglycoside-conjugated chlorambucil [60], sugars selected for conjugation ranged from native mammalian metabolites such as glucose to unnatural sugars such as lyxose and xylose.”
BackgroundInfluentialGriffin, J. F., Rampal, A. L., & Jung, C. Y. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.12.3759 · Cited by 61 · cited 1×
“cytochalasin B (a pan-GLUT transporter inhibitor [89, 90]).”
Briasoulis, E., Judson, I., Pavlidis, N., Beale, P., Wanders, J., Groot, Y., Veerman, G., Schuessler, M., Niebch, G., Siamopoulos, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3535 · Cited by 60
Improved brain delivery of AZT using a glycosyl phosphotriester prodrug
Namane, A., Gouyette, C., Fillion, M., Fillion, G., & Tam, H. D. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00094a018 · Cited by 59 · cited 1×
“The synthesis of glucose and mannose phosphotriester conjugates of the anti-retroviral nucleotide analog 3′-azido-3′-deoxythymidine (AZT) was also reported in 1991[32]; these derivatives were shown to have comparable antiviral efficacy and enhanced targeting to the central nervous system (presumably via GLUT transport…”
BackgroundOhba, S., Fujii, H., Ito, S., Fujimaki, M., Matsumoto, F., Furukawa, M., Yokoyama, J., Kusunoki, T., Ikeda, K., & Hino, O. (2009) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2009.00814.x · Cited by 56
Zhou, S., Wang, S., Wu, Q., Fan, J., & Wang, Q. (2008) · ORL · doi:10.1159/000124293 · Cited by 56
Grigsby, P. W., Winter, K. A., Wasserman, T. H., Marcial, V. A., Rotman, M. Z., Cooper, J. S., Keys, H. M., Asbell, S. O., & Phillips, T. L. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00054-1 · Cited by 56 · cited 1×
“However, these trials failed because the compounds were found to have dose-limiting toxicities at concentrations lower than their therapeutic doses [64].”
BackgroundA Phase I Study of the Metal Ionophore Clioquinol in Patients With Advanced Hematologic Malignancies
Schimmer, A. D., Jitkova, Y., Gronda, M., Wang, Z., Brandwein, J. M., Chen, C. I., Gupta, V. K., Schuh, A. C., Yee, K. W. L., Chen, J., et al. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.05.005 · Cited by 55 · cited 1×
“The 8-hydroxyquinolones, most notably clioquinol (5-chloro-7-iodo-8-hydroxyquinolone), have shown promise in early stage clinical trials as anticancer agents due to their scavenging of copper(II), a necessary co-factor in tumor growth [66].”
BackgroundLee, H. Y., Lee, J. J., Park, J., & Park, S. B. (2011) · Chemistry - A European Journal · doi:10.1002/chem.201002560 · Cited by 54
Dosio, F., Milla, P., & Cattel, L. (2010) · PubMed · Cited by 54
Liu, D.-Z., Sinchaikul, S., Reddy, P. V. G., Chang, M.-Y., & Chen, S.-T. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.008 · Cited by 53 · cited 2×
“The conjugate depicted in Figure 4b was the most potent of the all glycoconjugates tested [53, 54].”
BackgroundBriasoulis, E. C., Pavlidis, N. A., Terret, C., Bauer, J., Fiedler, W., Schöffski, P., Raoul, J., Hess, D., Selvais, R., Lacombe, D., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00629-4 · Cited by 49 · cited 1×
“Modest response was seen with glufosfamide alone in one phase II trial (2/35 patients with partial response, 11/35 with stable disease, 18/35 with disease progression) [42].”
BackgroundHerrmann, K., Benz, M., Krause, B. J., Pomykala, K. L., Buck, A. K., & Czernin, J. (2011) · PubMed · Cited by 46
Kumar, P., Shustov, G. V., Liang, H., Khlebnikov, V., Zheng, W., Yang, X., Cheeseman, C. I., & Wiebe, L. I. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2017336 · Cited by 44 · cited 2×
“The synthesis and preliminary biological evaluation of a series of glucose-azomycin adducts were recently reported in 2012 by Kumar and coworkers [63].”
BackgroundSynthesis and cytotoxic properties of new fluorodeoxyglucose-coupled chlorambucil derivatives
Reux, B., Weber, V., Galmier, M., Borel, M., Madesclaire, M., Madelmont, J., Débiton, E., & Coudert, P. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.03.038 · Cited by 43 · cited 2×
“In addition, peracetylated 2-fluorodeoxyglucose-conjugated chlorambucil was shown to demonstrate intracellular ROS production in L929 murine cells at 25 μM [58], suggestive of inducing DNA damage.”
BackgroundIfosfamide nephrotoxicity in pediatric cancer patients
Lee, B. S., Lee, J. H., Kang, H.-G., Hahn, H., Lee, J. H., Shin, H., Ha, I. S., Cheong, H. I., Ahn, H. S., & Choi, Y. J. (2001) · Pediatric Nephrology · doi:10.1007/s004670100658 · Cited by 43 · cited 1×
“This dose resulted in reversible renal tubular acidosis in 2/6 patients [37], presumably due to toxic ifosfamide metabolites generated during renal processing of the drug [38].”
BackgroundGLUT‐1 expression and response to chemoradiotherapy in rectal cancer
Brophy, S., Sheehan, K. M., McNamara, D. A., Deasy, J. M., Bouchier‐Hayes, D. J., & Kay, E. W. (2009) · International Journal of Cancer · doi:10.1002/ijc.24693 · Cited by 42
van den Bent, M. J., Grisold, W., Frappaz, D., Stupp, R., Desir, J. P., Lesimple, T., Dittrich, C., de Jonge, M. J. A., Brandes, A. A., Frénay, M., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg491 · Cited by 42 · cited 2×
“In the glioblastoma study, researchers did not comment as to whether glufosfamide crossed the blood-brain barrier, although no adverse neurological effects in any of the 31 patients were observed following an intravenous infusion of 1000 mL of a 5000 mg/m2 (approximately 156 mg/kg) glufosfamide solution over the cours…”
Synthesis and Biological Evaluation of Water Soluble Taxoids Bearing Sugar Moieties
Mandai, T., Okumoto, H., Oshitari, T., Nakanishi, K., Mikuni, K., Hara, K.-J., Hara, K., Iwatani, W., Amano, T., NAKAMURA, K., et al. (2001) · Heterocycles · doi:10.3987/com-00-s(i)34 · Cited by 40
Saigusa, S., Toiyama, Y., Tanaka, K., Okugawa, Y., Fujikawa, H., Matsushita, K., Uchida, K., Inoue, Y., & Kusunoki, M. (2011) · Surgery Today · doi:10.1007/s00595-011-0027-2 · Cited by 40
Halmos, T., Santarromana, M., Antonakis, K., & Scherman, D. (1997) · Carbohydrate Research · doi:10.1016/s0008-6215(96)00328-x · Cited by 39 · cited 13×
“This strategy is inspired by the widespread clinical use of 2-deoxy-2-( 18 F)uoro-D-glucose ( 18 F-FDG; Fig.”
BackgroundInfluentialD-Galactose as a Vector for Prodrug Design
Melisi, D., Curcio, A., Luongo, E., Morelli, E., & Rimoli, M. G. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611797183258 · Cited by 39 · cited 2×
“For instance, D-galactose, the C4 epimer of glucose, has been reported to possess an equivalent affinity and uptake rate by GLUT-1 compared to glucose [86].”
BackgroundReinhard, J., Hull, W. E., von der Lieth, C., Eichhorn, U., Kliem, H., Kaina, B., & Wießler, M. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010006e · Cited by 38 · cited 1×
“Wiessler and coworkers published two reports in 2001 [61, 62] on glucose conjugates of the benzylguanine class of inhibitors against the human DNA repair protein O6-methylguanineDNA methyltransferase (MGMT), an enzyme that is involved in DNA repair upon damage induced by alkylating chemotherapeutics.”
BackgroundKobayashi, M., Kaida, H., Kawahara, A., Hattori, S., Kurata, S., Hayakawa, M., Hirose, Y., Uchida, M., Kage, M., Fujita, H., et al. (2012) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31823924bb · Cited by 37
Inactivation ofO6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors
Reinhard, J., Eichhorn, U., Wießler, M., & Kaina, B. (2001) · International Journal of Cancer · doi:10.1002/ijc.1336 · Cited by 36 · cited 2×
“4 buffer for several days [62], although stability in serum or cell lysate was not reported.”
BackgroundInfluence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
Kerbusch, T., Mathôt, R. A. A., Keizer, H. J., Kaijser, G. P., Schellens, J. H. M., & Beijnen, J. H. (2001) · PubMed · Cited by 33
In Vivo Antitumor Activity of Novel Water-Soluble Taxoids
Mikuni, K., Nakanishi, K., Hara, K., Hara, K., Iwatani, W., Amano, T., NAKAMURA, K., Tsuchiya, Y., Okumoto, H., & Mandai, T. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.1155 · Cited by 32 · cited 1×
“A 2008 follow-up publication highlighted the in vivo potency of galactose-conjugated docetaxel (Figure 4a) in a syngeneic P388 murine leukemia tumor model compared to the aglycone [51], but did not characterize the mode of entry or potential cleavage products of the conjugate.”
BackgroundPatt, M., Sorger, D., Scheunemann, M., & Stöcklin, G. (2002) · Applied Radiation and Isotopes · doi:10.1016/s0969-8043(02)00186-0 · Cited by 31 · cited 1×
“these analogs have been shown to compete with D-glucose for cellular entry, suggesting their uptake is GLUT-mediated [81].”
BackgroundArafa, H. M. M. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.024 · Cited by 30 · cited 1×
“Glufosfamide is a prodrug, requiring cleavage of glucose via spontaneous hydrolysis or glycosidase activity [36] to liberate the active drug.”
BackgroundWarfarin Glycosylation Invokes a Switch from Anticoagulant to Anticancer Activity
Peltier, P., Timmons, S. C., Grandemange, A., Benoît, E., & Thorson, J. S. (2011) · ChemMedChem · doi:10.1002/cmdc.201100178 · Cited by 30 · cited 1×
“While most sugar conjugates lost their ability to prevent blood coagulation, some did show cytotoxicity in cancer cells, especially the amino-substituted D- and L-xylosides and lyxosides (D-lyxose-conjugated warfarin, which showed the most anticancer potency, is depicted in Figure 8e) [67].”
BackgroundGiaccone, G., Smit, E. F., de Jonge, M. J. A., Dansin, É., Briasoulis, E. C., Ardizzoni, A., Douillard, J.-Y., Spaëth, D., Lacombe, D., Barón, B., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.10.027 · Cited by 30 · cited 1×
“European glufosfamide clinical trials in patients with glioblastoma multiforme [46] and nonsmall cell lung carcinoma [47] have shown glufosfamide to have very modest, if any, efficacy.”
BackgroundStüben, J., Port, R. E., Bertram, B., Bollow, U., Hull, W. E., Schaper, M., Pohl, J., & Wießler, M. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050495 · Cited by 28 · cited 4×
“Encouragingly, radiolabeled glufosfamide was shown to localize to the site of a tumor in rats with prostate cancer, with labeled drug remaining at the site of the tumor for at least 24 hours [35], suggesting that it may be selectively taken up and retained by cancerous cells.”
BackgroundMethodInfluentialGlycosylated nordihydroguaiaretic acids as anti-cancer agents
Hwu, J. R., Hsu, C.-I., Hsu, M., Liang, Y., Huang, R. C. C., & Lee, Y. C. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.137 · Cited by 27 · cited 1×
“These include glucose, lactose, and galactose conjugates of the heat shock protein 90 inhibitor geldanamycin [70], glucose conjugates of the natural product cadalene [71], glycoconjugates of the DNA alkylator duocarmycin SA [72, 73], and glucose conjugates of the lipoxygenase inhibitor nordihydroguaiaretic acid [74].”
BackgroundAsymmetric Synthesis and Biological Evaluation of Glycosidic Prodrugs for a Selective Cancer Therapy
Tietze, L. F., von Hof, J. M., Krewer, B., Müller, M. M., Major, F., Schuster, H., Schuberth, I., & Alves, F. (2008) · ChemMedChem · doi:10.1002/cmdc.200800250 · Cited by 26 · cited 1×
“These include glucose, lactose, and galactose conjugates of the heat shock protein 90 inhibitor geldanamycin [70], glucose conjugates of the natural product cadalene [71], glycoconjugates of the DNA alkylator duocarmycin SA [72, 73], and glucose conjugates of the lipoxygenase inhibitor nordihydroguaiaretic acid [74].”
BackgroundEnhancement of Cyclopamine via Conjugation with Nonmetabolic Sugars
Goff, R. D., & Thorson, J. S. (2012) · Organic Letters · doi:10.1021/ol300703z · Cited by 25 · cited 1×
“All neoglycoside conjugates synthesized were shown to have increased growth proliferation inhibition compared to their aglycone in NCIH460 lung cancer cells, with D-threoside-conjugated cylopamine (Figure 8f) among the most potent of the set [68].”
BackgroundMiot-Noirault, É., Reux, B., Débiton, E., Madelmont, J., Chezal, J., Coudert, P., & Weber, V. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9371-0 · Cited by 24 · cited 2×
“parent compound chlorambucil was only modestly effective in one trial and ineffective in the second [59].”
BackgroundShimizu, T., Okamoto, I., Tamura, K., Satoh, T., Miyazaki, M., Akashi, Y., Ozaki, T., Fukuoka, M., & Nakagawa, K. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1028-3 · Cited by 22 · cited 1×
“The results of one phase I Japanese glufosfamide clinical trial in 13 patients with various solid tumors showed some promise (1/13 patients showed partial response, and 8/13 patients showed disease stabilization), [48] and phase II trials are ongoing.”
BackgroundMeasurement of sugar transport in single living cells
Barros, L. F. (1999) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s004240050843 · Cited by 22 · cited 1×
“Historically, competition with radiolabeled glucose [79] and changes in erythrocyte volume [85, 88] have been used in this model system.”
MethodChiorean, E. G., Dragovich, T., Hamm, J. T., Barrios, C. H., Gorini, C. F. N., Langmuir, V. K., Kroll, S., Jung, D. T., Tidmarsh, G. F., & Loehrer, P. J. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181979204 · Cited by 22 · cited 2×
“Combination of glufosfamide with the nucleoside analog gemcitabine – a standard-of-care chemotherapeutic in pancreatic cancer – yielded modest response in two trials on pancreatic adenocarcinoma patients [43, 44], with 4/29 patients treated with 4500 mg/m2 (approximately 140 mg/kg) glufosfamide experiencing nonreversi…”
BackgroundFluorine-19 NMR studies of glucosyl fluoride transport in human erythrocytes
London, R. E., & Gabel, S. A. (1995) · Biophysical Journal · doi:10.1016/s0006-3495(95)80051-2 · Cited by 19 · cited 11×
“However, glufosfamide's anticancer potency was markedly reduced upon co-treatment with 0.1 mM of the GLUT-1 transporter inhibitors phloretin and phlorizin, suggesting that the entry of glufosfamide into cells was at least partially GLUT receptor-mediated.”
BackgroundInfluentialEnhanced efficacy of 7-hydroxy-3-methoxycadalene via glycosylation in in vivo xenograft study
Lee, H. Y., Kwon, J., Koh, M., Cho, M., & Park, S. B. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.08.071 · Cited by 18 · cited 1×
“These include glucose, lactose, and galactose conjugates of the heat shock protein 90 inhibitor geldanamycin [70], glucose conjugates of the natural product cadalene [71], glycoconjugates of the DNA alkylator duocarmycin SA [72, 73], and glucose conjugates of the lipoxygenase inhibitor nordihydroguaiaretic acid [74].”
BackgroundDevalapally, H., Rajan, K. S., Akkinepally, R. R., & Devarakonda, R. K. (2008) · Drug Development and Industrial Pharmacy · doi:10.1080/03639040701744202 · Cited by 16 · cited 1×
“Galactose-conjugated drugs may be used to selectively target certain types of cancers known to highly express galactosidase enzymes, such as breast and colon cancers [87].”
BackgroundChiorean, E. G., Dragovich, T., Hamm, J. T., Langmuir, V. K., Kroll, S., Jung, D. T., Colowick, A. B., Tidmarsh, G. F., & Loehrer, P. J. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0559-8 · Cited by 13 · cited 1×
“Combination of glufosfamide with the nucleoside analog gemcitabine – a standard-of-care chemotherapeutic in pancreatic cancer – yielded modest response in two trials on pancreatic adenocarcinoma patients [43, 44], with 4/29 patients treated with 4500 mg/m2 (approximately 140 mg/kg) glufosfamide experiencing nonreversi…”
Background
Research works printed but not linked: 6
- Herrmann, 2011, Q. J. Nucl. Med. Mol. Imag., 55, 620
- Dosio, 2010, Curr. Opin. Invest. Drugs, 11, 1424
- Palit, 2005, Oncol. Rep., 14, 909
- Stewart, 2008, Oncol. Rep., 20, 1561
- Kerbusch, 2001, Drug Metab. Dispos., 29, 967
- Reske, 1997, J. Nucl. Med., 38, 1344
Cited by
Cu-Catalyzed Click Reaction in Carbohydrate Chemistry
Tiwari, V. K., Mishra, B. B., Mishra, K. B., Mishra, N., Singh, A. S., & Chen, X. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00408 · Cited by 862
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Glycosylation: mechanisms, biological functions and clinical implications
He, M., Zhou, X., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01886-1 · Cited by 499
Cu(I)-Catalyzed Click Chemistry in Glycoscience and Their Diverse Applications
Agrahari, A. K., Bose, P., Jaiswal, M. K., Rajkhowa, S., Singh, A. S., Hotha, S., Mishra, N., & Tiwari, V. K. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00920 · Cited by 472
Metadata
- Authors
- Calvaresi, E. C., & Hergenrother, P. J.
- Affiliations
- University of Illinois Urbana-Champaign (US)
- Corresponding author
- Hergenrother, Paul J.
- Venue
- Chemical Science
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2013
- Volume
- 4
- Issue
- 6
- Pages
- 2319
- ISSN
- 2041-6520 (ISSN-L)
- 2041-6539
- PMC
- PMC3784344
- OpenAlex
- W2110592482
- Cited by
- 398
- References
- 98
- Citations by year
- 2026: 16 · 2025: 42 · 2024: 29 · 2023: 32 · 2022: 41 · 2021: 24 · 2020: 42 · 2019: 43 · 2018: 32 · 2017: 28 · 2016: 40 · 2015: 17 · 2014: 10 · 2013: 2
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Chemical Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- U.S. Food and Drug Administration
- University of Illinois at Urbana-Champaign
- National Cancer Institute (F30CA168323)
- National Institute of General Medical Sciences (R01GM098453)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- glycoconjugates, glucose conjugation, tumor targeting, Warburg effect, aerobic glycolysis, cytotoxin, cancer metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.